Receiver operating characteristic analysis was used to analyze the performance of different anti‐EBV antibodies in distinguishing NPC and non‐NPC high‐risk populations, and EAD/IgA was found to be the most prominent marker, with an AUC of 0.903 (0.843–0.964), followed by TK/IgA, TK/IgG, and EAR/IgA (Table 1). The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.